CRESCENT BIOPHARMA, INC. Insider Trading Activity
Every SEC Form 4 insider transaction reported for CRESCENT BIOPHARMA, INC. (CBIO), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are CBIO insiders buying or selling?
In the last 12 months, CRESCENT BIOPHARMA, INC. insiders reported 2 open-market purchases ($30.6M) and 14 sales ($1.5M) — net buying of $29.1M. Since May 2018, Trabud has recorded 57 Form 4 filings for CBIO: 25 buys ($46.9M) and 32 sells ($16.6M).
Source: SEC EDGAR Form 4
Key Statistics (May 2018 – Sep 18, 2026)
Total Form 4 filings
57
SEC EDGAR
Insider filers
24
Insider buys (25)
$46.9M
Insider sells (32)
$16.6M
Insider sentiment
Net buyingNet insider flow of $30.3M in net buying since May 2018, and $29.1M in net buying over the last 12 months. 1 insider buy in the last 90 days.
Recent CBIO insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 18, 2026 | Ryan Lynch | Treasurer, Senior Vice President of Finance and Chief Accounting Officer. | Sale | 240 | $17.90 | $4.3K | SEC ↗ |
| Sep 18, 2026 | Jan Pinkas | Chief Scientific Officer | Sale | 658 | $17.90 | $11.8K | SEC ↗ |
| Sep 18, 2026 | Ellie Eunkyung Im | Chief Medical Officer | Sale | 623 | $17.90 | $11.2K | SEC ↗ |
| Sep 18, 2026 | Richard William Scalzo | Chief Financial Officer | Sale | 568 | $17.90 | $10.2K | SEC ↗ |
| Sep 18, 2026 | Barbara Harlin Bispham | General Counsel and Corporate Secretary. | Sale | 620 | $17.90 | $11.1K | SEC ↗ |
| Sep 18, 2026 | Joshua T Brumm | Chief Executive Officer | Sale | 9.4K | $16.91 | $159.8K | SEC ↗ |
| Sep 18, 2026 | Jonathan Mcneill | President and COO | Sale | 4.6K | $16.90 | $77.2K | SEC ↗ |
| Jul 20, 2026 | Tomas Kiselak | Director, 10% Owner | Purchase | 853.5K | $14.50 | $12.4M | SEC ↗ |
| Jun 23, 2026 | Ryan Lynch | Treasurer, Senior Vice President of Finance and Chief Accounting Officer. | Sale | 465 | $17.99 | $8.4K | SEC ↗ |
| Jun 23, 2026 | Jan Pinkas | Chief Scientific Officer | Sale | 1.3K | $17.99 | $23.2K | SEC ↗ |
| Jun 23, 2026 | Richard William Scalzo | Chief Financial Officer | Sale | 1.1K | $17.99 | $20.0K | SEC ↗ |
| Jun 23, 2026 | Barbara Harlin Bispham | General Counsel and Corporate Secretary. | Sale | 1.2K | $17.99 | $21.9K | SEC ↗ |
| Jun 23, 2026 | Ellie Eunkyung Im | Chief Medical Officer | Sale | 1.2K | $17.99 | $21.9K | SEC ↗ |
| Jun 23, 2026 | Jonathan Mcneill | President and COO | Sale | 20.5K | $17.99 | $369.7K | SEC ↗ |
| Jun 23, 2026 | Joshua T Brumm | Chief Executive Officer | Sale | 42.3K | $17.99 | $761.1K | SEC ↗ |
| Dec 8, 2025 | Tomas Kiselak | Director, 10% Owner | Purchase | 1.4M | $13.41 | $18.2M | SEC ↗ |
| Aug 9, 2024 | Raymond Debbane | 10% Owner | Sale | 322.4K | $0.19 | $61.2K | SEC ↗ |
| Aug 7, 2024 | Raymond Debbane | 10% Owner | Sale | 220.3K | $0.19 | $41.2K | SEC ↗ |
| Aug 5, 2024 | Raymond Debbane | 10% Owner | Sale | 349.8K | $0.20 | $71.1K | SEC ↗ |
| Jul 30, 2024 | Raymond Debbane | 10% Owner | Sale | 1.4M | $0.23 | $315.3K | SEC ↗ |
| Jun 24, 2024 | Edwin Rock | Chief Medical Officer | Purchase | 305.0K | $0.26 | $78.8K | SEC ↗ |
| Jun 20, 2024 | Brian M. Hahn | SVP Finance, CFO | Purchase | 17.5K | $0.25 | $4.3K | SEC ↗ |
| Sep 25, 2023 | Edwin Rock | Chief Medical Officer | Purchase | 65.4K | $1.38 | $90.3K | SEC ↗ |
| May 18, 2023 | Brian M. Hahn | SVP Finance, CFO | Sale | 3.7K | $1.95 | $7.2K | SEC ↗ |
| May 11, 2023 | JUNIUS DANIEL M | Director | Purchase | 30.0K | $1.56 | $46.8K | SEC ↗ |
Showing the 25 most recent of 57 Form 4 filings for CRESCENT BIOPHARMA, INC..
Most active CBIO insiders
- Amaury Wittouck8 filings
- Brian M. Hahn5 filings
- Edwin Rock4 filings
- JUNIUS DANIEL M4 filings
- Scott D Sandell4 filings
Ask anything about CBIO insider activity
Use Trabud's AI agent to query CRESCENT BIOPHARMA, INC.'s Form 4 history in plain English — "Show me CBIO CEO purchases this year" or compare it against any other ticker.
Open the AI agentCBIO insider trading FAQ
Are CRESCENT BIOPHARMA, INC. insiders buying or selling?
In the last 12 months, CRESCENT BIOPHARMA, INC. insiders reported 2 open-market purchases ($30.6M) and 14 sales ($1.5M) — net buying of $29.1M. Since May 2018, Trabud has recorded 57 Form 4 filings for CBIO: 25 buys ($46.9M) and 32 sells ($16.6M). Over the full record that is net buying of $30.3M.
How many insiders trade CBIO stock?
24 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for CRESCENT BIOPHARMA, INC.. The most recent filing was accepted on Sep 18, 2026.
Where does Trabud get CBIO insider trading data?
All CBIO insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.